WillItSurvive
Medical technology and health companies · United States

Helix

helix.com ↗

Helix runs population genomics tests and licenses linked clinical-genomic data to health systems and drug makers.

Losing its protection
Assessed 31 July 2026 · Evidence as of 31 July 2026
The structural protection is eroding.
On the recordSince 31 July 2026 · Checkable from 12 months · Every call on the record Checkpoint: Next funding round or disclosure of data-licensing margins, first since the 2021 Series C
The call

The data and hospital contracts look hard to replace, but five years without a funding round and wildly different revenue numbers leave the business case unproven.

Helix combines genetic testing with patient health records and insurance claims to help pharmaceutical companies and hospitals find people for drug trials and personalized medicine. The company built a database of 500,000 people's genetic and medical histories over more than a decade, runs its own certified lab, and has signed long-term contracts with 16 health systems and major drug makers like AstraZeneca, which makes the service hard to copy quickly. However, Helix has not raised new funding since 2021, its revenue figures don't match public records, and the entire personalized genetics market has collapsed (rival companies like Invitae went bankrupt in 2024), so no one knows if the company is close to making money or running low on cash, which is the one thing that will determine whether the business survives.

Why
01
AI pressure: Tempus. Tempus builds its own AI-native linked genomic-clinical dataset, still oncology-focused, but could push into population genomics next. Could AI do the core job? Unlikely.
02
Bigger players: Illumina. Early investor Illumina cut ties in 2019 and would face channel conflict selling against its own hospital sequencing customers. Could a giant copy it? No, they are blocked.
03
What protects it. 500,000+ linked clinico-genomic records across 16 health systems, tied to CLIA lab infrastructure and multi-year contracts, hard to copy fast.
What would change this call
Helix announces a new equity round or acquisition by mid-2027. Shows whether the business is funded on good terms or forced into a down-round or sale.
GenoSphere dataset reaches or misses 1 million linked records by 2027. Indicates whether the core data moat is still scaling as claimed.
Tempus announces health-system population-genomics deals beyond oncology. Would show a direct competitor encroaching on Helix's health-system niche.
Key numbers
  • 500,000+ linked records across 16 health systems (2026-06)
  • No new equity round since $50M Series C (2021-06)
  • Revenue estimates range from $128.9M to $380M (2026)
Named risks
  • No new equity round since June 2021 creates a five-year funding gap in a capital-intensive lab business. Severity: high
  • Revenue and headcount figures conflict wildly across data trackers with no audited disclosure. Severity: medium
  • Population genomics category graveyard, including 23andMe's 2026 collapse and Invitae's 2024 bankruptcy. Severity: high
  • AI-native rival Tempus building an overlapping linked clinico-genomic dataset threatens data-licensing moat. Severity: medium
  • Structural channel conflict with Illumina since the 2019 relationship end limits certain partnership paths. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Tempusgaining onAI-native oncology genomics firm building an overlapping linked clinical-genomic dataset as of 2026
IlluminacontestingEarly Helix investor that ended the commercial relationship in 2019, now a structural rival
23andMegaining on23andMe's 2026 collapse removed a major consumer genomics rival from the category
Invitaegaining onInvitae's 2024 bankruptcy reduced clinical genomics competition in Helix's space
Quest DiagnosticscontestingNamed broader lab-services competitor in the diagnostics market
Questions people ask
Is Helix in financial trouble?
There is no documented evidence of financial distress, but Helix's funding picture since its 2021 Series C ($50 million, as of June 2021) remains unclear, which is a real gap in the record. The company has an active watch-item asking whether it confirms a new equity round of at least $50 million by December 2027.
Who are Helix's biggest competitors?
Tempus and GeneDx compete most directly for the same pharma-licensing and health-system data deals, with GeneDx expanding into AI-driven genomic interpretation through its Fabric Genomics acquisition. Larger players like Tempus (over $600 million 2024 revenue) and Natera (over $1.5 billion 2024 revenue, about 30% growth) dwarf Helix in scale, though as of June 2026 there is no documented case of Helix losing a customer to either direct rival.
Is Helix at risk from AI?
AI replacement risk looks unlikely for now. Helix's shield is a regulated CLIA/CAP lab paired with over 500,000 linked clinico-genomic records as of June 2026, built through in-house sequencing and 16 health-system partnerships. That combination of infrastructure and long-run data, averaging 13 years of EHR history and 8 years of claims history per record, is hard for an AI model to replicate on its own.
What is Helix's biggest risk?
The clearest risk is that large lab incumbents like Labcorp and Quest Diagnostics run the sequencing volume needed to build a competing linked-data network for pharma, a threat status marked 'building' in the July 2026 assessment. A second watch-item is growth execution: Helix aims for 1 million linked GenoSphere records within 18 months of June 2026, up from over 500,000 that month, and that target still needs to be hit.
Could a bigger company just copy what Helix does?
It is possible but not proven yet. Labcorp and Quest Diagnostics have the lab-testing scale to build a competing linked clinico-genomic data network, and this giant-threat status is marked 'building' as of the July 2026 assessment. Helix's counter is its combination of in-house sequencing, 13 years of average EHR history, and 8 years of claims history across 16 health-system partnerships (as of June 2026), which is not something a new entrant can assemble quickly.
Timeline
  • 2026-07-07Announced multi-year data-licensing agreement with AstraZeneca
  • 2026-07-01Launched GenoSphere MCP connector inside Anthropic's Claude Science workbench
  • 2026-06-16Two new health systems launched Helix Genomic Advantage program
  • 2026-06-11Launched AI-powered Cohort Builder with embedded AI Research Assistant
  • 2026-06-02GenoSphere passed 500,000 linked clinico-genomic records across 16 health systems
  • 2025-01-15Helix Research Network added three new health system members
  • 2021-06-03Closed $50M Series C led by Warburg Pincus, DFJ Growth, Kleiner Perkins, Mayo Clinic, Temasek
  • 2021-05-06James Lu appointed CEO, Marc Stapley became Executive Chairman
  • 2019-05Helix cut jobs and closed two offices during consumer-to-enterprise pivot
  • 2015-07-15Founded in San Mateo, California by Justin Kao, James Lu, and Scott Burke
Head to head
Color Health vs HelixHelix vs Natera
Revision history
31 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources